Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

University of Pittsburgh Cancer Institute Cancer Services

Neither a doctor nor a teaching hospital

Research payments

$15,912,665

2,290 payments

Through program year 2025, University of Pittsburgh Cancer Institute Cancer Services is reported as receiving $15,912,665 in research payments, across 2,290 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $4,115,838 793
2024 Research $2,988,033 587
2023 Research $3,485,593 317
2022 Research $1,184,503 193
2021 Research $1,636,743 212
2020 Research $1,690,978 108
2019 Research $810,979 80

Breakdown

Who paid Research payments · program years 2019–2025
  1. Regeneron Pharmaceuticals, Inc. $1,786,319 421 payments
  2. Merck Sharp & Dohme Corporation $1,739,703 9 payments
  3. Celgene Corporation $1,241,566 30 payments
  4. GlaxoSmithKline, LLC. $970,200 91 payments
  5. Sanofi US Services Inc. $925,233 53 payments
  6. Genentech, Inc. $919,498 135 payments
  7. Exelixis Inc. $833,579 170 payments
  8. E.R. Squibb & Sons, L.L.C. $819,728 44 payments
  9. Amgen Inc. $756,887 16 payments
  10. Pfizer Inc. $685,695 90 payments
Studies the money was for Research payments · program years 2019–2025
  1. First-in-Human, Phase 1,1b, Open-label, Multicenter Study of Bifunctional EGFR,TGF Fusion Protein BCA101 Monotherapy and in Combination Therapy in Patients with EGFR-Driven Advanced Solid Tumors $1,241,230 2 payments
  2. A Randomized, Open-label, Active-control, Phase 2/3 Study of First-line Intratumoral CMP-001 in Combination With Intravenous Nivolumab Compared to Nivolumab Monotherapy in Subjects With Unresectable or Metastatic Melanoma $808,904 163 payments
  3. A Phase 1 Dose Escalation and Cohort Expansion Study of Tsr-022, An An $779,736 53 payments
  4. A Phase 1, Open-Label, Multiple-Ascending Dose Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of KD033 in Subjects With Metastatic or Locally Advanced Solid Tumors. $708,229 20 payments
  5. Phase 1- ST-001 Monotherapy escalation + escalation in combination with Cetux and Rituximab (CC-95251-ST-001) (BMS Study Number: CA059-P01) $437,741 1 payment
  6. First-in-Human, Phase 1,1b, Open-label, Multicenter Study of Bifunctional EGFR,TGF Fusion Protein BCA101 Monotherapy and in Combination Therapy in Patients with EGFR-Driven Advanced Solid Tumors $397,180 1 payment
  7. Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) $355,570 204 payments
  8. An Open-Label, Dose Escalation, Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Tak-676 As A Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced Or Metastatic Solid Tumors $348,725 12 payments
  9. A Multicenter, Open-label, Phase 2 Study of Intratumoral CMP-001 in Combination With Intravenous Nivolumab in Subjects With Refractory Unresectable or Metastatic Melanoma $342,178 39 payments
  10. A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects with Metastatic Colorectal Cancer $316,336 28 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record